Literature DB >> 8556006

Outcomes of black and white hypertensive individuals after 30 years of follow-up.

D T Lackland, J E Keil, P C Gazes, C G Hames, H A Tyroler.   

Abstract

Outcomes of a 30-year follow-up for the participants of the Charleston Heart Study were studied with elevated blood pressure assessed using various classifications. The traditional categories of > or = 140/90 mmHg, > or = 160/95 mmHg and isolated systolic hypertension, as well as high normal and the four stages of high blood pressure were utilized in analyses. Prevalence rates of hypertension were, in general, higher among blacks compared to whites. Blacks had higher prevalence rates of hypertension and greater prevalence of high blood pressure at younger ages. Risk ratios were higher for black and white hypertensives than their normotensive counterparts. Blacks were found to have substantially higher population attributable risk proportions, particularly at the higher blood pressure categories. The results suggest that the standard clinical classifications of hypertension as related to mortality are appropriate for blacks and white.

Entities:  

Mesh:

Year:  1995        PMID: 8556006     DOI: 10.3109/10641969509033654

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  9 in total

1.  Racial differences in hypertension: implications for high blood pressure management.

Authors:  Daniel T Lackland
Journal:  Am J Med Sci       Date:  2014-08       Impact factor: 2.378

2.  Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "research-to-practice" project from the diabetes collaborative registry.

Authors:  Suzanne V Arnold; Leo Seman; Fengming Tang; Poghni A Peri-Okonny; Keith C Ferdinand; Sanjeev N Mehta; Abhinav Goyal; Laurence S Sperling; Mikhail Kosiborod
Journal:  Diabetes Obes Metab       Date:  2018-09-25       Impact factor: 6.577

Review 3.  Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.

Authors:  Daniel T Lackland; Edward J Roccella; Anne F Deutsch; Myriam Fornage; Mary G George; George Howard; Brett M Kissela; Steven J Kittner; Judith H Lichtman; Lynda D Lisabeth; Lee H Schwamm; Eric E Smith; Amytis Towfighi
Journal:  Stroke       Date:  2013-12-05       Impact factor: 7.914

4.  Thirty-year Survival for Black and White Hypertensive Individuals in the Evans County Heart Study and the Hypertension Detection and Follow-up Program.

Authors:  Daniel T Lackland; Brent M Egan; William K Mountford; Andrea D Boan; Denis A Evans; Gregory Gilbert; Daniel L McGee
Journal:  J Am Soc Hypertens       Date:  2008 Nov-Dec

5.  Does prehypertension represent an increased risk for incident hypertension and adverse cardiovascular outcome?

Authors:  Stephen P Glasser; Jan N Basile; Daniel T Lackland
Journal:  Hypertension       Date:  2009-08-31       Impact factor: 10.190

6.  30 Year patterns of mortality in Tobago, West Indies, 1976-2005: impact of glucose intolerance and alcohol intake.

Authors:  Mariam Molokhia; Dorothea Nitsch; Alan Leslie Patrick; Paul McKeigue
Journal:  PLoS One       Date:  2011-01-25       Impact factor: 3.240

7.  Racial and Ethnic Subgroup Disparities in Hypertension Prevalence, New York City Health and Nutrition Examination Survey, 2013-2014.

Authors:  Kezhen Fei; Jesica S Rodriguez-Lopez; Marcel Ramos; Nadia Islam; Chau Trinh-Shevrin; Stella S Yi; Claudia Chernov; Sharon E Perlman; Lorna E Thorpe
Journal:  Prev Chronic Dis       Date:  2017-04-20       Impact factor: 2.830

8.  Generalizability and effect size of the impact of anti-hypertensive medication adherence on long-term cardio-cerebrovascular mortality.

Authors:  Dhvani Shihora; Kristy Bono; Anurag Modak
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-04-12       Impact factor: 2.885

9.  Racial disparities in hypertension.

Authors:  Daniel T Lackland
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-09       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.